Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16847608 | 0.85 | MAPT (0.49) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL19017845 | 0.85 | MAPT (0.49) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL18332009 | 0.83 | CA1 (0.45) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL22239381 | 0.79 | TDP1 (0.46) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL12285414 | 0.79 | PSMB8 (0.47) | MAPTTDP1PAX8NPSR1CA1 | |
| SCHEMBL20067638 | 0.78 | SPHK1 (0.49) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL5545897 | 0.77 | ANPEP (0.46) | CA1CA2 | |
| SCHEMBL5545902 | 0.77 | ANPEP (0.46) | CA1CA2 | |
| SCHEMBL17650866 | 0.76 | CA1 (0.50) | MAPTTDP1KDM4EGAAGLA | |
| SCHEMBL20067639 | 0.76 | CA1 (0.64) | MAPTTDP1KDM4EGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | MAPT 1689/4885TDP1 4439/4885KDM4E 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.